Personalised medicine – a patient‘s perspective

David H.-U. Haerry

- **Positive Council Switzerland**
  www.positivrat.ch

POSITIVRAT
CONSEIL POSITIF
CONSIGLIO POSITIVO
CUSSEGL POSITIV
POSITIVE COUNCIL

Personalised interventions in HIV

Current treatment decisions rely on 2 biomarkers, VL & CD4 count. Additional tests help personalising care & improve treatment outcomes

- **Hypersensitivity testing pre-abacavir use** (HLA B*5701 genetic test)
- **TDM widely used in Switzerland**
- **Resistance testing at baseline**
- **Kidney function at baseline**
- **Studies show genetic factors influence plasma concentrations in NNRTI** (983T>C genotypes)
- **Tropism testing pre-maraviroc use**

Challenges

Not comprehensive

- Formal pharmaco-genetic clinical trials difficult to finance
- Major reimbursement challenges to overcome
  - Who pays for a sensitivity test before using drug X?
  - Pricing models if large indications turn orphan & require a multitude of personalised interventions
- Data protection if blood samples are collected, stored & shared nationally / globally
- Complex evaluation of new tests, in particular those without binary read out
- Time consuming processes to update treatment guidelines, labels & reimbursement – adaptive models required
- How to keep patients informed & trust the system?

Reflections on solutions

- Health expenses considered as cost, not an investment. No or insufficient instruments to model cost & QoL effectiveness for new interventions
- Narrow focus on cost containment but little concern about system robustness & stability
- Price setting system laid out for medicines with daily intake – new models needed for interventions taken once or short term & providing long lasting effect
- Transparent & adaptive regulatory & reimbursement decisions
- Digitalisation in health care – Scandinavian disease registries show the future (SWEDEHEART). Disease registries require strong public funding & long term strategy
- Authorise collection rather than use of data
- Citizen controlled data storage & sharing. My data should benefit society, not Google & Co.
- Philosophical question: More regulation or more dialogue?
- Have the priorities right & muddle through wisely